Home » Stocks » Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc. (CNAT)

May 27, 2020 - CNAT merged into HSTO
Stock Price: $0.556 USD 0.000 (0.00%)
Updated May 26, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 18.44M
Revenue (ttm) 14.69M
Net Income (ttm) -10.12M
Shares Out 33.17M
EPS (ttm) -0.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day May 26, 2020
Last Price $0.556
Previous Close $0.556
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.541 - 0.594
Day's Volume 1,696,913
52-Week Range 0.230 - 1.070

More Stats

Market Cap 18.44M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 33.17M
Float 32.19M
EPS (basic) n/a
EPS (diluted) -0.31
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 130,661
Short Ratio 0.37
Short % of Float 0.41%
Beta 1.84
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.26
PB Ratio 1.05
Revenue 14.69M
Operating Income n/a
Net Income -10.12M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin -12.32%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -21.85%
ROE -49.07%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0
What these ratings mean

Analyst Consensus: n/a

Price Target

$15.00*
Low
15.0
Current: $0.556
High
15.0
Target: 15.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Conatus Pharmaceuticals Inc.
Country United States
Employees 5
CEO Steven J. Mento

Stock Information

Ticker Symbol CNAT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CNAT
IPO Date July 25, 2013

Description

Conatus Pharmaceuticals, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.